Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States
Authors:
- Stephen R. ColeSCStephen R. Cole
- Jessie K. EdwardsJEJessie K. Edwards
- for the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) InvestigatorsFIfor the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Investigators
Open Access
- 12 May 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 64 (11) , 1591-1596
Abstract
The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integrase inhibitors is unknown. We use observational data from the Centers for AIDS Research Network of Integrated Clinical Systems and the Centers for Disease Control and Prevention to estimate 4-year risk of AIDS and all-cause mortality among 415 patients starting a raltegravir regimen compared to 2646 starting an efavirenz regimen (both regimens include emtricitabine and tenofovir disoproxil fumarate). We account for confounding and selection bias as well as generalizability by standardization for measured variables, and present both observational intent-to-treat and per-protocol estimates. At treatment initiation, 12% of patients were female, 36% black, 13% Hispanic; median age was 37 years, CD4 count 321 cells/µL, and viral load 4.5 log10 copies/mL. Two hundred thirty-five patients incurred an AIDS-defining illness or died, and 741 patients left follow-up. After accounting for measured differences, the 4-year risk was similar among those starting both regimens (ie, intent-to treat hazard ratio [HR], 0.96 [95% confidence interval {CI}, .63–1.45]; risk difference, −0.9 [95% CI, −4.5 to 2.7]), as well as among those remaining on regimens (ie, per-protocol HR, 0.95 [95% CI, .59–1.54]; risk difference, −0.5 [95% CI, −3.8 to 2.9]). Raltegravir and efavirenz-based initial antiretroviral therapy have similar 4-year clinical effects. Vigilance regarding longer-term comparative effectiveness of HIV regimens using observational data is needed because large-scale experimental data are not forthcoming.Keywords
Funding Information
- National Institutes of Health (R01AI100654, R24AI067039, P30AI50410, P30AI094189)
This publication has 24 references indexed in Scilit:
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Beyond the intention-to-treat in comparative effectiveness researchClinical Trials, 2011
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic AnalysesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Observational Studies Analyzed Like Randomized ExperimentsEpidemiology, 2008
- Cohort profile: the Centers for AIDS Research Network of Integrated Clinical SystemsInternational Journal of Epidemiology, 2008
- Marginal Structural Models for Estimating the Effect of Highly Active Antiretroviral Therapy Initiation on CD4 Cell CountAmerican Journal of Epidemiology, 2005
- Evaluating Medication Effects Outside of Clinical Trials: New-User DesignsAmerican Journal of Epidemiology, 2003
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958